Skip to main content
. Author manuscript; available in PMC: 2013 Mar 14.
Published in final edited form as: Cancer Biol Ther. 2008 Nov 4;7(11):1753–1755. doi: 10.4161/cbt.7.11.6723

Figure 1.

Figure 1

Histology and immunophenotypic marker characterization of the JH-EsoAd1 cell line. (A) Histology of the primary tissue demonstrates gland formation, consistent with an adenocarcinoma. (B) Histology of the metaplastic Barrett epithelium in the periphery of the tumor. (C) Immunohistochemical analysis of p53 (DO-1 antibody) in the primary tumor demonstrates nuclear overexpression in the neoplastic cells. (D) Phase contrast microscopy of the JH-EsoAd1 cell line growing in tissue culture. (E) Immunohistochemical analysis of cytokeratin expression on JH-EsoAd1 cells shows positivity for this epithelial marker. (F) Immunohistochemical analysis of vimentin expression on JH-EsoAd1 cells shows negativity for this mesenchymal marker. (G) Immunohistochemical analysis of p53 expression (DO-1 antibody) shows nuclear overexpression in JH-EsoAd1, as observed in the primary tissue. (H) Sequence analysis of exon 8 of the p53 gene, in the patient’s lymphocytes, shows wild type sequence in codon 266. (I) Sequence analysis of exon 8 of the p53 gene, in the cell line derived material shows a homozygous G797A somatic mutation that results in a non-synonymous Gly266Glu alteration.

HHS Vulnerability Disclosure